11.10.26 -- Is Your Supply Chain Ready For The End Of Class VI?

Gain insight into a disposable pen that is a proven, globally adopted drug delivery platform with over 175 million units sold, supporting diverse therapies in 40+ countries.

A unified, modular biomanufacturing ecosystem combining rapid CLD, flexible purification, and scalable global capacity can accelerate production and strengthen supply agility amid rising demand.

Smart analytical decisions made early can prevent costly issues later. Real-world examples show how right-sized analytics enable smoother scale-up and fewer late-stage surprises.

Technology transfer succeeds through trust, shared knowledge, and disciplined execution. See how collaboration, strong documentation, and digital tools reduce risk on the path to GMP.

Poor manufacturability and immunogenicity can delay development. Learn how early developability assessments support IND readiness.

Engaging manufacturing partners earlier in biologics development mitigates critical scale-up risks. Explore how aligning technical strategies early preserves process history and simplifies compliance.

Driven by metabolic and oncology successes, the expanding peptide therapeutics market faces critical challenges requiring early, customized drug product development, stability, and safety strategies.

For complex projects involving oral solid dosage (OSD) and sterile drug products, selecting the ideal CDMO can play a pivotal role in determining the success of a drug candidate.

Standardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.